Tech Transfer eNews Blog

Google’s venture capital arm joins £4m funding round for Oxford vaccine startup

By Jesse Schwartz
Published: April 5th, 2017

GV, the venture capital branch of Google, has joined a £4 million (over $4.97M US) investment round for an Oxford University start-up that is developing a “biotech superglue” to create new vaccines.

SpyBiotech is based on research from Oxford’s biochemistry department and the Jenner Institute focused on separating the bacteria that causes strep throat. When separated, the two parts of the bacteria have a strong tendency to regroup, creating the “biotech superglue” that can be harnessed to bond things together. SpyBiotech aims to redirect this bond to develop effective vaccines for fast-spreading epidemics.

Oxford Sciences Innovation, a university start-up fund, is contributing to the £4m investment round alongside GV.

“We view this superglue technology as a game changer to enable faster development of effective vaccines against major global diseases,” says Sumi Biswas, associate professor at the Jenner Institute of Oxford and co-founder of SpyBiotech. “We are excited to begin the journey of taking this versatile and innovative approach forward and moving our new vaccines from the laboratory to human clinical testing.”

GV has backed 19 biotech companies across the globe. General partner Tom Hulme comments, “We’re looking forward to working with a team of world-class scientists with extensive experience in vaccine development — spanning from vaccine design through to Phase II clinical trials — to develop more effective vaccines for a wide range of global diseases.”

Source: Business Insider

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment